前列腺癌局灶放疗加量的应用:放射肿瘤科医生的观点与实施障碍
该研究于2022年12月至2023年2月通过在线问卷向全球放射肿瘤科医生调查前列腺癌局灶放疗加量的使用情况与实施障碍,共263人参与。43%的参与者常规使用该技术,完全泌尿生殖亚专科医生中为61%。主要障碍包括MRI与CT配准准确性(37%)、额外毒性风险(35%)和高质量MRI可及性(29%)。
要点
- 43%的受访放射肿瘤科医生常规使用前列腺癌局灶放疗加量,完全泌尿生殖亚专科医生中为61%。
- 高收入国家和中低收入国家中,常规使用局灶加量的参与者均不足半数。
- 最常提及的障碍为MRI与CT配准准确性(37%)、额外毒性风险(35%)和高质量MRI可及性(29%)。
核心结论
- 在一项显示患者获益且未增加毒性的随机试验发表两年后,近半数受访放射肿瘤科医生常规提供局灶放疗加量。
- 进一步推广该技术可能受益于高质量MRI可及性提高、更好的MRI与CT模拟图像配准算法、医生对获益-危害比的培训以及MRI上前列腺病灶勾画的培训。
研究设计与样本
- 邀请放射肿瘤科医生于2022年12月和2023年2月完成在线问卷,评估其前列腺内局灶加量的使用情况。
- 邀请通过电子邮件列表、群组短信平台和社交媒体在全球放射肿瘤科医生中分发。
- 共263名放射肿瘤科医生参与,参与者最多来自美国(42%)、墨西哥(13%)和英国(8%)。
- 大多数参与者在学术医疗中心工作(52%),并认为其执业至少部分为泌尿生殖亚专科(74%)。
主要发现
- 总体43%的参与者报告常规使用前列腺内局灶加量。
- 完全泌尿生殖亚专科医生更可能实施局灶加量,61%报告常规使用。
- 在高收入国家和中低收入国家,常规使用局灶加量的参与者均不足半数。
- 最常提及的障碍为对MRI与CT配准准确性的担忧(37%)、对额外毒性风险的担忧(35%)和获取高质量MRI的挑战(29%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a recent phase III randomized control trial, delivering a focal radiotherapy (RT) boost to tumors visible on MRI was shown to improve disease-free survival and regional/distant metastasis-free survival for patients with prostate cancer-without increasing toxicity. The aim of this study was to assess how widely this technique is being applied in current practice, as well as physicians' perceived barriers toward its implementation. METHODS: We invited radiation oncologists to complete an online questionnaire assessing their use of intraprostatic focal boost in December 2022 and February 2023. To include perspectives from a broad range of practice settings, the invitation was distributed to radiation oncologists worldwide via email list, group text platform, and social media. RESULTS: 263 radiation oncologist participants responded. The highest-represented countries were the United States (42%), Mexico (13%), and the United Kingdom (8%). The majority of participants worked at an academic medical center (52%) and considered their practice to be at least partially genitourinary (GU)-subspecialized (74%). Overall, 43% of participants reported routinely using intraprostatic focal boost. Complete GU-subspecialists were more likely to implement focal boost, with 61% reporting routine use. In both high-income and low-to-middle-income countries, less than half of participants routinely use focal boost. The most cited barriers were concerns about registration accuracy between MRI and CT (37%), concerns about risk of additional toxicity (35%), and challenges to accessing high-quality MRI (29%). CONCLUSIONS: Two years following publication of a randomized trial of patient benefit without increased toxicity, almost half of the radiation oncologists surveyed are now routinely offering focal RT boost. Further adoption of this technique might be aided by increased access to high-quality MRI, better registration algorithms of MRI to CT simulation images, physician education on benefit-to-harm ratio, and training on contouring prostate lesions on MRI.
引用
- Zhong AY, Lui AJ, Katz MS, et al. Use of focal radiotherapy boost for prostate cancer: radiation oncologists' perspectives and perceived barriers to implementation. Radiat Oncol. 2023. PMID: 37950310. doi:10.1186/s13014-023-02375-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。